Cargando…

Real-World Use of Alirocumab: Experience from a Large Healthcare Provider

With the emerging use of anti-PCSK9 monoclonal antibodies for lowering low-density lipoprotein cholesterol (LDL-C) levels, real-world evidence (RWE) is needed to evaluate drug effectiveness. This study aimed to characterize new users of alirocumab and evaluate its effectiveness in achieving LDL-C ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elis, Avishay, Melzer Cohen, Cheli, Chodick, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917622/ https://www.ncbi.nlm.nih.gov/pubmed/36769732 http://dx.doi.org/10.3390/jcm12031084

Ejemplares similares

Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel
por: Melzer Cohen, Cheli, et al.
Publicado: (2020)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study
por: Melzer Cohen, Cheli, et al.
Publicado: (2017)

Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
por: Schechter, Meir, et al.
Publicado: (2021)

Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study
por: Melzer Cohen, Cheli, et al.
Publicado: (2021)

Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
por: Weil, Clara, et al.
Publicado: (2022)

Correction to: Epidemiology and Economic Burden of Atopic Dermatitis: Real-World Retrospective Data from a Large Nationwide Israeli Healthcare Provider Database
por: Weil, Clara, et al.
Publicado: (2022)

PEARL: A Non-interventional Study of Real-World Alirocumab Use in German Clinical Practice
por: Parhofer, Klaus G., et al.
Publicado: (2019)

829. Identification of Congenital Cytomegalovirus Infection Using Real-World Healthcare Data
por: Weil, Clara, et al.
Publicado: (2020)

Healthcare Utilization and Prevalence of Symptoms in Women with Menopause: A Real-World Analysis
por: Sharman Moser, Sarah, et al.
Publicado: (2020)

Progressive supranuclear palsy’s economical burden: the use and costs of healthcare resources in a large health provider in Israel
por: Barer, Yael, et al.
Publicado: (2023)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

Use of Healthcare Services Following Severe Hypoglycemia in Patients with Diabetes: Analysis of Real-World Data
por: Goldstein, Dalit, et al.
Publicado: (2016)

A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes
por: Melzer-Cohen, Cheli, et al.
Publicado: (2019)

Pain Pharmacotherapy in a Large Cohort of Patients with Osteoarthritis: A Real-World Data Analysis
por: Fallach, Noga, et al.
Publicado: (2021)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
por: Ceballos-Macías, José Juan, et al.
Publicado: (2020)

Secular trends in testosterone- findings from a large state-mandate care provider
por: Chodick, Gabriel, et al.
Publicado: (2020)

Epidemiology of Progressive Supranuclear Palsy: Real World Data from the Second Largest Health Plan in Israel
por: Barer, Yael, et al.
Publicado: (2022)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

RE: Praluent (Alirocumab)-Induced Renal Injury
por: Rosenson, Robert S., et al.
Publicado: (2017)

Mortality Benefit of Alirocumab: A Bayesian Perspective
por: Labos, Christopher, et al.
Publicado: (2019)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
por: East, Cara, et al.
Publicado: (2022)

Real World Analysis of Small Cell Lung Cancer Patients: Prognostic Factors and Treatment Outcomes
por: Moser, Sarah Sharman, et al.
Publicado: (2021)

Real-World Utilization of Molnupiravir during the COVID-19 Omicron Surge in Israel
por: Weil, Clara, et al.
Publicado: (2023)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
por: Gao, Fei, et al.
Publicado: (2022)

Alirocumab in Post ACS Patients - Saving Lives at a Premium
por: George, Melvin, et al.
Publicado: (2022)

A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
por: McDonagh, Marian, et al.
Publicado: (2016)

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
por: Rosenberg, Vered, et al.
Publicado: (2023)

Alirocumab after acute coronary syndrome in patients with a history of heart failure
por: White, Harvey D, et al.
Publicado: (2021)

Treatment patterns, persistence with therapy, and outcomes of ustekinumab in Crohn's disease: Real‐world data analysis
por: Banon, Tamar, et al.
Publicado: (2022)

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
por: Banach, Maciej, et al.
Publicado: (2021)

Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults
por: Schechter, Meir, et al.
Publicado: (2022)

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis
por: Gendelman, Omer, et al.
Publicado: (2020)

The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis
por: Barer, Yael, et al.
Publicado: (2022)

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q1ggqofinfbclcitd8266tqdu7